Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth-Ann G Coller

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Vaccine|October 14, 2015
Preclinical and clinical development of a dengue recombinant subunit vaccineSusan B Manoff, Sarah L George, Andrew J Bett, et al.
Viruses|March 27, 2025
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge ModelAmy C Shurtleff, John C Trefry, Sheri Dubey, et al.
Vaccine|January 26, 2010
Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeysDavid E Clements, Beth-Ann G Coller, Michael M Lieberman, et al.
Vaccine|September 25, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infantsDavid Greenberg, Patricia A Hoover, Timo Vesikari, et al.
Vaccine|June 26, 2017
Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemicBeth-Ann G Coller, Jeffrey Blue, Rituparna Das, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adultsKevin L Russell, Richard E Rupp, Javier O Morales-Ramirez, et al.
Vaccines|September 23, 2022
Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP <i>Zaire ebolavirus</i> Vaccine to Inform Marburg Virus and <i>Sudan ebolavirus</i> VaccinesBeth-Ann G Coller, William Lapps, Mahum Yunus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2023
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and AdultsAndrew W Lee, Ken Liu, Edouard Lhomme, et al.
The Lancet. Infectious Diseases|August 8, 2024
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in BrazilMauricio L Nogueira, Monica A T Cintra, José A Moreira, et al.
The New England Journal of Medicine|January 31, 2024
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and AdultsEsper G Kallás, Monica A T Cintra, José A Moreira, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Vaccine|October 14, 2015
Preclinical and clinical development of a dengue recombinant subunit vaccineSusan B Manoff, Sarah L George, Andrew J Bett, et al.
Viruses|March 27, 2025
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge ModelAmy C Shurtleff, John C Trefry, Sheri Dubey, et al.
Vaccine|January 26, 2010
Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeysDavid E Clements, Beth-Ann G Coller, Michael M Lieberman, et al.
Vaccine|September 25, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infantsDavid Greenberg, Patricia A Hoover, Timo Vesikari, et al.
Vaccine|June 26, 2017
Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemicBeth-Ann G Coller, Jeffrey Blue, Rituparna Das, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adultsKevin L Russell, Richard E Rupp, Javier O Morales-Ramirez, et al.
Vaccines|September 23, 2022
Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP <i>Zaire ebolavirus</i> Vaccine to Inform Marburg Virus and <i>Sudan ebolavirus</i> VaccinesBeth-Ann G Coller, William Lapps, Mahum Yunus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2023
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and AdultsAndrew W Lee, Ken Liu, Edouard Lhomme, et al.
The Lancet. Infectious Diseases|August 8, 2024
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in BrazilMauricio L Nogueira, Monica A T Cintra, José A Moreira, et al.
The New England Journal of Medicine|January 31, 2024
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and AdultsEsper G Kallás, Monica A T Cintra, José A Moreira, et al.
Pageof 3